What Lineagen does

Lineagen, Inc. is a US-based private genetic diagnostics holding company headquartered in Salt Lake City, employing 51-100 people. Operating primarily through its wholly-owned subsidiary Bionano Laboratories, the company delivers clinical genetic evaluation services anchored on Optical Genome Mapping (OGM) technology, which detects genome-wide structural variants at higher resolution than traditional cytogenetic methods. Its test menu spans chromosomal microarray (FirstStepDx PLUS), whole exome sequencing (NextStepDx PLUS), Fragile X testing, and a suite of OGM-Dx assays covering postnatal whole genome structural variant assessment, prenatal testing, facioscapulohumeral muscular dystrophy type 1 (FSHD1), and (suspended) hematologic malignancy applications. Genetic counseling services are bundled with clinical reporting to support patients and families.

The company serves two primary customer segments: healthcare providers (clinical laboratories, hospitals, geneticists, and other clinicians ordering tests for patient diagnosis) and researchers (academic and industry users accessing OGM Data Services for structural variation studies). Revenue is generated through a direct laboratory testing model via a single CLIA-certified laboratory; healthcare providers submit specimens and receive interpreted results with genetic counseling support, while researchers initiate OGM projects through the company website. Pricing is not publicly disclosed. Distribution is domestic single-country only, with no international markets served and no announced geographic expansion.

The company has raised approximately $61M in cumulative disclosed venture funding across seven rounds between 2008 and 2015, with the most recent priced round being a $12.17M Series 3 in January 2015 led by HealthQuest Capital. The current operating state shows a stable but constrained footprint: the website is active, but multiple clinical OGM services have been moved to a 'Suspended Services' page, and no funding rounds, acquisitions, or major leadership additions have been reported in the years following the 2015 round.

Name

Lineagen

Legal name

Lineagen, Inc.

Website

https://lineagen.com

Company type

Private

Founded year

2026

Operating status

Operating

Headcount range

51–100 employees

Short description

Lineagen, through its Bionano Laboratories subsidiary, provides clinical genetic testing and counseling services built on Optical Genome Mapping and related technologies, serving healthcare providers diagnosing pediatric neurodevelopmental, prenatal, and neuromuscular disorders, plus researchers using OGM data services.

Ownership category

akta.pro rank

Product category

Clinical Genetic Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Genetic Counseling & Prenatal Testing Telehealth (carrier screening, NIPT counseling) (HLALAHAK)

Keywords

• Genetic testing services
• Clinical diagnostics
• Optical genome mapping
• Pediatric genetic disorders
• Genetic counseling services

Headquarters

HQ city

Salt Lake City

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels1 record

Core offering

Lineagen, operating through its subsidiary Bionano Laboratories, provides clinical genetic testing services including chromosomal microarray (FirstStepDx PLUS), whole exome sequencing (NextStepDx PLUS), Fragile X testing, and Optical Genome Mapping (OGM)-based diagnostic tests (OGM-Dx) for pediatric neurodevelopmental disorders, prenatal conditions, neuromuscular disorders, and hematologic malignancies. The company complements its testing portfolio with genetic counseling services and offers OGM Data Services for research applications exploring structural variation.

Product overview

Lineagen offers a portfolio of clinical genetic testing services and research-oriented OGM (Optical Genome Mapping) services. The clinical portfolio includes chromosomal microarray (FirstStepDx PLUS), whole exome sequencing (NextStepDx PLUS), Fragile X testing, and a suite of OGM-Dx tests covering prenatal, postnatal, neuromuscular (FSHD1), and hematologic malignancy applications. These services are complemented by genetic counseling services for patient and family support. The OGM Data Services offering provides researchers access to optical genome mapping technology for structural variation research projects.

Differentiator

Problem solved

Functional benefit

Brands

• OGM-Dx: Optical Genome Mapping diagnostic tests for various conditions including postnatal whole genome structural variant assessment, prenatal testing, FSHD1, and hematologic malignancies (HemeOne).

Products and services

• FirstStepDx PLUS Chromosomal Microarray Chromosomal microarray testing service designed for pediatric neurodevelopmental disorder assessments, providing copy number variation analysis for clinical diagnosis.
• NextStepDx PLUS Whole Exome Sequencing Whole exome sequencing service for comprehensive genetic analysis targeting pediatric neurodevelopmental conditions.
• Fragile X Test Genetic test for Fragile X syndrome detection used in pediatric neurodevelopmental disorder assessments.
• OGM-Dx Postnatal Whole Genome SV Optical genome mapping diagnostic test for detecting structural variants in postnatal whole genome analysis.
• OGM-Dx Prenatal Whole Genome SV Optical genome mapping diagnostic test for prenatal structural variant assessment.
• OGM-Dx FSHD1 Optical genome mapping diagnostic test specifically designed for facioscapulohumeral muscular dystrophy type 1 detection.
• OGM-Dx HemeOne Optical genome mapping diagnostic test for hematologic malignancies assessment (currently suspended).
• Genetic Counseling Services Professional genetic counseling services to support patients and families throughout the genetic testing process, including result interpretation and guidance.
• OGM Data Services Optical genome mapping data services for researchers to explore structural variation in research projects, including project initiation and data analysis support.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Myriad Genetics: Specialized genetic testing company focused on hereditary cancer, women's health, and mental health. Comparable to Lineagen as a specialty genetics lab serving clinicians with proprietary panels and counseling-adjacent services.
• GeneDx: Clinical genomics lab offering exome and genome sequencing with strong focus on pediatric rare disease and neurodevelopmental disorders — directly overlapping Lineagen's core pediatric neurodevelopmental franchise.
• Invitae: Genetic testing company with broad hereditary disease and pediatric testing menu including CMA, exome, and rare disease panels, serving similar clinician customer base as Lineagen.
• Ambry Genetics: Clinical genetic testing lab specializing in hereditary cancer, exome sequencing, and rare disease diagnostics with genetic counseling support — highly comparable specialty lab model.
• Natera: Genetics-focused diagnostics company with significant prenatal testing (NIPT) and oncology businesses. Comparable on the prenatal and reproductive health testing side of Lineagen's OGM-Dx prenatal offering.
• PreventionGenetics: Clinical genetic testing lab focused on hereditary disease and rare disorder panels, including pediatric and neurodevelopmental indications — direct specialty genetics competitor with comparable clinical menu.
• Fulgent Genetics: Genetic testing company offering NGS-based panels, exome, and whole genome services to clinicians and patients. Comparable to Lineagen as a specialty genetics lab with technology-forward test menu.

Broad incumbents

• Quest Diagnostics: National reference laboratory offering comprehensive genetic and molecular diagnostics, including prenatal screening and pediatric testing. Competes with Lineagen on the broader clinical menu while offering much wider geographic reach.
• Laboratory Corporation of America (Labcorp): Major reference lab with extensive genetic and molecular diagnostics capabilities including prenatal, pediatric, and specialty genetic testing. Comparable as a broad incumbent that competes with specialty labs like Lineagen.

Others

• Bionano Genomics: Developer of the optical genome mapping (OGM) instrument platform that underlies Lineagen's OGM-Dx tests. Functions as an enabling technology supplier and parent brand — adjacent rather than competitive.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lineagen